Affiliations: Department of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Correspondence:
[*]
Corresponding author: Yu-Jie Wang, Department of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang, China. E-mail:mustafa621@outlook.com
Abstract: OBJECTIVE: microRNAs (miRNAs) plays an important role in tumor development
and progression and act as oncogenes or tumor suppressor genes in the
carcinogenesis process. miRNA is stable in serum, and recent studies have
demonstrated the feasibility of using circulating miRNA as biomarkers in
cancer patients. However, currently, no serum biomarkers for the early
diagnosis and prognosis of renal cell carcinoma (RCC) have been reported.
Therefore, a new molecular marker for early diagnosis and evaluation of
recurrence after surgery is required. Our purpose was to identify miRNA
signatures that could distinguish the serum of RCC patients from matched
healthy controls and validate identified miRNAs as potential biomarkers for
RCC. METHOD: Serum samples from 30 RCC patients were collected before and 1
month after surgery. 30 cancer-free blood donor volunteers with no history of
any cancer were recruited from the same institute. miR-21 and miR-106a
expression levels were determined by real-time PCR. RESULT: The serum miR-21 level was significantly higher in RCC patients (median, 8.34) than in healthy
control individuals (median, 0.70; p= 0.001).
A month after surgery, serum miR-21 levels (median, 0.69) were significantly reduced (p= 0.032). The serum
miR-106a level was higher in RCC patients (median, 8.99) compared with controls (median, 0.96; p= 0.000), while miR-106a levels (median, 1.01) were
reduced a month after surgery (p= 0.028).
The expression level of miR-21 and miR-106 a in RCC patients increased significantly, while miR-21 and miR-106a decreased after surgery.
This outcome suggests that serum miR-21 and miR-106a expression level was closely related with kidney cancer tissue. CONCLUSION: We conclude that serum miR-21 and miR106a are expected to be
molecular markers for RCC.
